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Introduction
 Carvedilol is a nonselective beta-adrenoceptor and 
selective alpha 1-adrenoceptor blocker that is widely 
used in hypertensive and/or chronic heart failure 
patients. Unlike classic beta-blockers, carvedilol has 
additional endothelium-dependent vasodilatory 
effects1)~3). Several recent studies have reported that 
carvedilol has beneficial effects in patients with 
cardiogenic failure and shock4)~6). The carvedilol or 
metoprolol European trial demonstrated that carvedilol 
protected better against vascular events such as 
myocardial infarction and stroke than metoprolol in 
patients with chronic heart failure5). The findings of the 
carvedilol post-infarct survival control trial indicated 
that carvedilol treatment offers an early benefit in 
clinically stabilized patients with post-myocardial 
infarction left ventricular dysfunction6). Furthermore, 
beta-blocker therapy during the perioperative period 
may improve morbidity and mortality rates in high-risk 
patients with ischemic heart disease7)8). 
 Several studies have shown that carvedilol and 
beta-blockers generally suppress lipopolysaccharide 
(LPS)-induced cytokine and tissue factor production 
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Abstract
 Purpose: Carvedilol, a nonselective beta-adrenoceptor and selective alpha 1-adrenoceptor blocker, has 
high efficacy and is widely used in hypertensive and/or cardiac failure patients. However, few studies 
have examined the effects of carvedilol on septic shock. The present study evaluated the effects of 
carvedilol pretreatment in cecal ligation and puncture (CLP)-induced septic shock in rats. 
 Methods: Male Sprague Dawley rats (n = 90) were randomly assigned to one of the following three 
groups (n = 30 per group): control group (no medication), high-dose carvedilol group (10 mg/kg/day, 
orally administered for 5 days), and low-dose carvedilol group (2 mg/kg/day, orally administered for 5 
days). Septic shock was induced by CLP, and the animals received no other therapies. Mortality was 
calculated for 5 days after CLP. Arterial blood gases and plasma cytokine concentrations were measured 
in 36 additional male rats 12 hr after CLP. 
 Results: Mortality rates 5 days after CLP were 76.7%, 86.7%, and 86.7% in the control, high-dose, and 
low-dose groups, respectively; there were no significant differences among the three groups. Furthermore, 
observed decreases in base excess, increases in lactate concentrations, and increases in cytokine 
concentrations in the carvedilol-treated groups did not differ from those in the control group. 
 Conclusions: The present findings indicate that orally administered carvedilol has no beneficial effects 
on mortality and inflammatory responses in CLP-induced septic shock in rats, suggesting that carvedilol 
may not contribute to recovery from septic shock. 
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Abbreviations: CLP, cecal ligation and puncture; IL, interleukin; TNF, tumor necrosis factor; LPS, lipopolysaccharide; 
BE, base excess; Lac, lactate
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in vitro and attenuate myocardial dysfunction in 
septic animals9)~11). An open-label randomized phase 2 
study in clinical practice indicated that in patients 
with septic shock, administration of the short-acting 
beta-blocker esmolol helped in maintaining the heart 
rate and decreased the risk of death significantly 
(esmolol group: 49.4%; control group: 80.5%; p < 
0.01)12). Moreover, the study suggested that the use of 
esmolol in patients with septic shock might improve 
myocardial movement and oxygen consumption 
efficiency. However, few studies have investigated 
the effect of beta-blockers on septic shock in patients 
who were previously treated with a beta-blocker. 
Therefore, in the present study, we aimed to evaluate 
the effects of carvedilol pretreatment on mortality and 
inflammatory responses in rats with cecal ligation and 
puncture (CLP)-induced sepsis. 
Materials and Methods
 The experimental protocol in this study was 
approved by the Animal Care Committee of our 
institute (#143309), and the animals were cared for 
and handled in accordance with the National 
Institutes of Health guidelines. 
Effect of carvedilol on mortality in septic shock rats 
 Ninety male Sprague Dawley rats were randomly 
allocated to one of the following three groups (n = 30 
each): control (no medication), high-dose carvedilol 
(10 mg/kg/day) for 5 days, or low-dose carvedilol (2 
mg/kg/day) for 5 days. These doses were determined 
according to the findings of the past studies13). In our 
preliminary study, the animals received carvedilol 
with either food or water, and its administration with 
food was shown to decrease heart rate markedly. 
Therefore, in the present study, carvedilol was 
administered with food by crushing and mixing it 
well into the rat chow. The rats were bred freely in 
cages, and water and food were freely available. The 
rats ate 25 mg of food per day, and carvedilol was 
administered at doses of 4 mg/day (high-dose group) 
or 0.8 mg/day (low-dose group). Each rat ate all of 
the allowed food during the 5-day period.
 After pretreatment with carvedilol for 5 days, all 
rats were anesthetized by the intraperitoneal injection 
of pentobarbital 40 mg/kg. Then, a laparotomy was 
performed, and the cecum immediately distal to the 
ileocecal valve was ligated. An appendix ligation 
puncture model in which two punctures were made 
with an 18-gauge needle was used in this study. The 
mortality up to 5 days post-CLP was observed. 
Effects of carvedilol on inflammatory responses in 
rats with septic shock 
 An additional 36 male Sprague Dawley rats were 
randomly assigned to one of the following three 
groups: control (no medication, n = 15), high-dose 
carvedilol (10 mg/kg/day orally administered for 5 
days, n = 10), and low-dose carvedilol (2 mg/kg/day, 
orally administered for 5 days, n = 11). All animals 
were anesthetized with an intraperitoneal injection of 
pentobarbital, and CLP was performed as described 
above. 
 At 12 hr after CLP, arterial blood samples (0.25 
ml) were collected to measure pH, arterial carbon 
dioxide tension (PaCO2), arterial oxygen tension 
(PaO2), and base excess (BE) and lactate (Lac) 
concentrations. Additional arterial blood samples 
(1.5 ml) were collected to measure plasma cytokine 
levels, including tumor necrosis factor (TNF)-alpha, 
interleukin (IL)-1beta, and IL-6, at 12 hr after CLP. 
All of the cytokine concentrations were measured 
using enzyme-linked-immunosorbent assay kits 
(BioSource, Camarillo, CA, USA). 
Statistical analysis
 Statistical power calculated14) using a one-sided 
design with a significance level of 5% and a 
probability of 80% showed that a minimum of 30 rats 
was needed in each group to detect a difference of at 
least 30% between the control and treatment groups13). 
 Data are presented as mean ± standard deviation. 
Mortality rates among the groups were compared 
using the Kaplan-Meier and Mantel-Cox tests. 
Differences between groups were analyzed by 
unpaired t test. Significance was defined as values of 
p < 0.05. The statistical analysis was performed using 
StatView software (version 5.0 for Macintosh; 
Abacus Concepts, Berkeley, CA, USA). 
Results
Mortality rates 
 A total of 30 rats received high-dose carvedilol, 
another 30 received low-dose carvedilol, and the 
remaining 30 received no medication (control group). 
Thereafter, CLP was performed and the survival 
status for 5 days was observed. As shown in Fig. 1, 
the first death occurred the next day in the control 
group, and 23 of 30 rats died by the fifth day; hence, 
the mortality rate was 76.7%. On the other hand, in 
the high- and low-dose groups, 26 of 30 rats died by 
the fifth day, and the mortality rates were 86.7% in 
both conditions. The statistical analysis of these 
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survival rates using the Kaplan-Meier and Mantel-
Cox tests revealed that the p value was 0.5434 (i.e., 
no statistically significant difference).
Blood gases
 Ten rats received high-dose carvedilol and another 
11 rats received low-dose carvedilol for 5 days. The 
remaining 15 animals were included in the control 
group. CLP was performed in these rats and BE and 
Lac concentrations were measured 12 hr later. As 
shown in Fig.2, BE concentrations were -4.07 ± 5.38 
mmol/l, -2.39 ± 2.97 mmol/l, and -1.57 ± 1.7 mmol/
l in the control, high-dose, and low-dose groups, 
respectively. There were no significant differences 
among the three groups (p = 0.3786, control versus 
high-dose group; p = 0.1518, control versus low-dose 
group; and p = 0.4432, high-dose versus low-dose 
group). Similarly, Lac concentrations were 4.85 ± 
3.96 mmol/l, 7.40 ± 6.15 mmol/l, and 2.57 ± 1.03 
mmol/l for the control, high-dose, and low-dose 
groups, respectively. There were no significant 
differences among the three groups (p = 0.2269 
control versus high-dose group, p = 0.2502 control 
versus low-dose group, and p = 0.1018 high-dose 
versus low-dose group). In other words, there were no 
significant differences in BE and Lac concentrations in 
all the groups at 12 hr after CLP, regardless of the dose 
of carvedilol. 
Plasma cytokine concentrations 
 TNF-alpha, IL-1 beta, and IL-6 levels were 
measured in the rats described above. As shown in 
Fig.3, TNF-alpha levels were 7.0 ± 3.9 pg/ml, 5.8 
± 5.3 pg/ml, and 10.3 ± 6.8 pg/ml for the control, 
high-dose, and low-dose groups, respectively. There 
were no significant differences among the three 
groups (p = 0.3336, control versus high-dose group; 
p = 0.4066, control versus low-dose group; and p = 
0.1965, high-dose versus low-dose group). Similarly, 
IL-1 beta levels were 135 ± 29 pg/ml, 146 ± 16 pg/
ml and 149 ± 13 pg/ml for the control, high-dose, 
and low-dose groups, respectively. There were no 
significant differences among the three groups (p = 
0.3054, control versus high-dose group; p = 0.1543, 
control versus low-dose group; and p = 0.6124, high-
dose versus low-dose group). Furthermore IL-6 levels 
were 44.5 ± 6.9 pg/ml, 44.1 ± 3.4 pg/ml and 44.4 
± 2.6 pg/ml for the control, high-dose, and low-dose 
groups, respectively. There were no significant 
differences among the three groups (p = 0.8532, 
control versus high-dose group; p = 0.9686, control 
versus low-dose group; and p = 0.7880, high-dose 
versus low-dose group).
Fig. 1. Survival curves for the control, high-dose carvedilol, and 
low-dose carvedilol groups after cecal ligation and puncture.
     High-dose group, 
     Low-dose group, 
     Control group
Fig. 2.  Base excess (BE)(top) and plasma lactate (Lac)(bottom) 
concentrations 12 hr after the cecal ligation and puncture. The 
mean BE levels were -4.07 ± 5.38, -2.39 ± 2.97, and -1.57 ± 1.7 
mmol/l in the control, high-dose, and low-dose groups, 
respectively, while the mean Lac levels were 4.85 ± 3.96, 7.40 
± 6.15, and 2.57 ± 1.03 mmol/l in the control, high-dose, and 
low-dose groups, respectively.
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Discussion 
 CLP in rats is associated with hypotension and 
metabolic acidosis as well as elevated plasma 
cytokine concentrations. The mortality rate 5 days 
after CLP was extremely high in the control and 
carvedilol-treated groups. Carvedilol administration 
did not alleviate CLP-induced metabolic acidosis or 
elevate Lac concentrations. Thus, CLP-induced 
mortality and inflammation remained the same after 
the oral administration of carvedilol as that in the 
control group.
 Numerous recent studies have demonstrated the 
efficacy of carvedilol for treating chronic heart 
failure1)2)4)5). In addition, many studies have reported 
that carvedilol has beneficial effects in patients soon 
after a myocardial infarction, and beta-blocker 
therapy during the perioperative period showed 
improved morbidity and mortality rates in high-risk 
patients with ischemic heart disease6)~8). These 
studies suggested that early and continuous 
administration of carvedilol might have beneficial 
effects in patients with ischemic heart disease. 
Recently, the number of patients receiving oral 
carvedilol has increased owing to its beneficial 
effects of carvedilol; however, some of these patients 
developed septic shock. On the other hand, few 
studies have examined the effects of oral ly 
administered carvedilol on septic shock. Therefore, 
in the present study, we aimed to evaluate the effects 
of orally administered carvedilol on mortality and 
inflammatory responses in rats with CLP-induced 
septic shock. The results of this study indicate that 
the oral administration of carvedilol after CLP-
induced septic shock in rats has no beneficial effects 
on mortality and inflammatory responses. These 
findings suggest that carvedilol therapy may have no 
beneficial effects on the recovery of patients with 
septic shock. 
 The mechanisms underlying the beneficial effects 
of beta-blockers on sepsis and septic shock have 
been reported in several studies. Sasao et al. showed 
that landiolol, a beta-blocker, has potent negative 
chronotropic effects in rabbits15). Hagiwara et al. also 
showed that landiolol has protective effects against 
acute lung injury and cardiac dysfunction in a rat 
sep t ic model16). Seps i s causes sympathe t ic 
hypertonia. The above studies suggested that a 
possible mechanism underlying the effects of beta-
b lockers could be i t s inh ib i tory e ffec ts on 
sympathetic hypertonia. However, in the present 
study, the effect of carvedilol pretreatment was not 
observed in rats with septic shock, suggesting that 
pretreatment with beta-blockers may disturb the 
sympathetic nerve tone when sepsis becomes under 
sympathetic nerve tone suppressed condition. In 
addition, because carvedilol has both alpha and beta 
blocking agents, the alpha-blocker may inhibit to 
protect against organ dysfunctions. 
 T h e p r e s e n t  f i n d i n g s s h o w t h a t  o r a l l y 
administered carvedilol increases Lac and cytokine 
concentrations after CLP, and Lac response in 
Fig. 3.  Plasma tumor necrosis factor (TNF)-alpha (top), 
inter leukin (IL) -1 beta (middle) , and IL-6 (bottom) 
concentrations at 12 hr after cecal ligation and puncture. The 
mean TNF-alpha levels were 7.0 ± 3.9, 5.8 ± 5.3, and 10.3 ± 
6.8 pg/ml in the control, high-dose, and low-dose groups, 
respectively. The mean IL-1beta levels were 135 ± 29, 146 ± 16, 
and 149 ± 13 pg/ml in the control, high-dose, and low-dose 
groups, respectively. The mean IL-6 levels were 44.5 ± 6.9, 
44.1 ± 3.4, and 44.4 ± 2.6 pg/ml in the control, high-dose, 
and low-dose groups, respectively.
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carvedilol-treated rats deteriorated in a manner 
similar to that observed in control rats. Several 
studies have examined the relationship among beta-
blockers and cytokine and Lac concentrations9)~11). 
Mizuochi et al.9) showed that carvedilol inhibits LPS-
induced production of TNF-alpha and tissue factors 
in human monocytes in vitro. Suzuki et al.10) reported 
that esmolol, a beta-blocker, attenuated the elevation 
of TNF-alpha and Lac concentrations in septic rats. 
The findings of the present study differ from those of 
previous studies possibly due to a decrease in cardiac 
performance induced by carvedilol and failure to 
improve peripheral circulation systemically. We 
previously showed that the oral administration of 
carvedi lo l increases the morta l i ty ra te and 
exacerbates the inflammatory responses to severe 
hemorrhagic shock in rats13). These differences 
suggest that administration of beta-blockers inhibits 
sepsis-induced increase in cardiac performance and 
improves the survival rate after septic shock in rats; 
however, further investigations are required to clarify 
this point. 
 Determining whether a dose-response relationship 
exists between carvedilol and outcomes is important. 
Therefore, the present study evaluated the effects of 
two different carvedilol doses (2 and 10 mg/kg/day) 
on mortality and the inflammatory responses after 
septic shock in rats. The results indicate that 
carvedilol has no beneficial effects on CLP-induced 
mortality and inflammatory responses to septic shock 
in rats regardless of dose. Thus, it can be suggested 
that dose-response carvedilol therapy may have no 
beneficial effects on the recovery of patients with 
septic shock. 
 Clinically, it is important to understand whether 
carvedilol has beneficial effects in patients who 
received treatment before the onset of septic shock. 
We previously showed that the oral administration of 
carvedilol increases the mortality rate and exacerbates 
the inflammatory responses to severe hemorrhagic 
shock in rats13), indicating that carvedilol may worsen 
the recovery of severe hemorrhagic shock in patients. 
Nevertheless, the present study showed that carvedilol 
does not impair the recovery from CLP-induced septic 
shock in rats. 
 There may be several important explanations for 
the differences in results between the present study 
and previous studies. First, the extent of disability 
caused by CLP in this study may be relatively severe. 
The mortality rate in all the groups 5 days after CLP 
was extremely high. Further studies using models 
with low or moderate mortality rates for the control 
group may be needed. Second, it is possible that the 
duration of carvedilol administration was relatively 
short. Further investigations are needed to clarify the 
importance of duration of carvedilol administration. 
Finally, the present study used normal Sprague 
Dawley rats. Clinically, carvedilol is generally 
administered to hypertensive patients; therefore, 
further studies are needed in hypertensive rats. 
 In conclusion, the present study shows that the 
oral administration of carvedilol increased the 
mortality rate and exacerbated the inflammatory 
responses to CLP-induced septic shock in rats in a 
manner similar to that observed without carvedilol 
administration. Although further investigations are 
required, the current findings suggest that carvedilol 
may have no beneficial effects on the recovery of 
patients with septic shock. 
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